infliximab plus methotrexate

DRUG2 trials

Sponsors

Saitama Medical Center. Saitama Medical University, Helsinki University Central Hospital

Conditions

Juvenile Idiopathic ArthritisRheumatoid Arthritis

Phase 3

Aggressive Combination Drug Therapy in Very Early Polyarticular Juvenile Idiopathic Arthritis

CompletedNCT01015547

Helsinki University Central HospitalJuvenile Idiopathic Arthritis

Start: 2003-05-31End: 2013-12-31Updated: 2015-10-15

Unknown Phase

"Effect examination of infliximab to the effect insufficient example and the example of effect decrease of the 1st TNF inhibitor in rheumatoid arthritis "

Active, not recruitingJPRN-UMIN000007786

Saitama Medical Center. Saitama Medical UniversityRheumatoid Arthritis

Start: 2012-05-01Target: 40Updated: 2026-06-29

Related Papers

Economic evaluation of infliximab, synthetic triple therapy and methotrexate in the treatment of newly diagnosed juvenile idiopathic arthritis.

2022-11-162 citations

Health-related quality of life during early aggressive treatment in patients with polyarticular juvenile idiopathic arthritis: results from randomized controlled trial.

2019-12-1613 citations